A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

NCT06208826 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

268

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Toripalimab
RADIATION: Radiation Therapy
DRUG: Cisplatin

Sponsor

Tianjin Medical University Cancer Institute and Hospital